Exagen Inc. (NASDAQ:XGN – Get Rating) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 21,500 shares, an increase of 32.7% from the February 13th total of 16,200 shares. Based on an average trading volume of 28,500 shares, the short-interest ratio is currently 0.8 days. Currently, 0.2% of the shares of the stock are sold short.
Exagen Stock Up 0.4 %
NASDAQ XGN opened at $2.43 on Friday. Exagen has a 1-year low of $2.10 and a 1-year high of $9.44. The company has a market cap of $39.51 million, a price-to-earnings ratio of -1.07 and a beta of 1.26. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average of $2.67 and a 200-day moving average of $2.91.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the company. Canaccord Genuity Group reduced their price target on Exagen from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 15th. Canaccord Genuity Group dropped their price objective on Exagen from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 15th. Cowen dropped their price objective on Exagen to $7.00 in a research note on Thursday, November 17th. Finally, BTIG Research dropped their price objective on Exagen from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, November 17th.
Institutional Trading of Exagen
Exagen Inc develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
- Get a free copy of the StockNews.com research report on Exagen (XGN)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.